AIDA EU project

💭"In Spain, we have moved to quadruple therapies, a shift associated with an increase in global efficacy from 83.5% to 97%." During the AIDA Webinar Series, Javier Tejedor from University Hospital of Cabueñes gave us a glimpse into new data. Ask for a link to the webinar!

Data from the US shows that gastric cancer is increasing in women at an annual rate of almost 5% per year. These are exactly the questions that Dr. Constanza Camargo and Tania Fleitas explored in the first session of the AIDA Webinar Series Ask for a link to the webinar!

❗Understanding your treatment is part of the treatment itself. At AIDA, this is precisely the kind of evidence-based insight we aim to support and build upon, helping clinicians communicate more effectively with their patients and ultimately improving treatment outcomes.

ℹ️TOGAS data validates new endoscopic scoring system for Gastric Cancer Risk. We're proud to share that PhD candidate Noa Kapteijn from @ErasmusMC presented important findings at the Digestive Disease Days (DDD) in Veldhoven. Congratulations to Noa and the entire team! 👏

Behind the AI, there are people. Today, on International Women's Day, we want to shine a light on just some of the exceptional women making AIDA possible. Many talented women across the AIDA consortium who are working every day to change the future of gastric cancer prevention.

A previous version of this post included an error. The correct number is 38,000.

How does AI learn which H. pylori treatment works best? By analysing 3,805 real European patients and assigning each treatment a "Q score" based on actual success rates. Nature Communications, 2025 | DOI: 10.1038/s41467-025-61329-5 @hpeureg

In Europe, ≥60s treated for H. pylori were more often on other meds (55% vs 27% in ages 18–59) yet showed the same excellent adherence: 97% in both groups. Full article 👉nature.com/articles/s4159…

🌍 Today we celebrate women shaping the future of science 💜 “As part of AIDA, I see how women lead, innovate, and transform health through teamwork and support.” – Olga P. Nyssen #womeninscience

On #WorldCancerDay , we're asked: Can AI place people at the centre of gastric cancer care? Our answer: AI becomes people-centred when it recognises that behind every data point is a human story. Technology could empower clinicians to see each patient more clearly.

📢 Half the world carries H. pylori. Treatment is getting harder. EU registry (2024, ~4k pts): 1st-line resistance: clarithro 23%, metro 27%, quinolones 18%. After failure: clarithro 49%, metro 41%. AIDA uses AI to tailor therapy + boost 1st-try cure. @hpeureg

Can AI "Read" Pathology? 🔬 At the AIDA Project, we are leveraging machine learning and deep learning models trained on diverse data. Our AI learns the "language" of disease to offer real-time diagnostic support. 👉 Watch through the video to learn about AI training.

🔎How is the AIDA AI-Clinician trained? The AI-Clinician learns from real-world clinical experience captured in the @hpeureg registry. Using reinforcement learning, the AI trains like a physician, gaining experience. Ultimately, it recommends personalised first-line therapies.

As we welcome 2026, the AIDA consortium is incredibly proud of what we've accomplished together in 2025! This past year brought remarkable milestones. 🎉 First-ever webinar series, study publications, major conferences, media recognition, and more! See our 2025 journey!👇

✨PhD candidate Noa Kapteijn (Erasmus MC) presented new findings validating the EGGIM scoring system with support from AIDA and TOGAS. EGGIM shows high accuracy in detecting advanced gastric risk stages, helping improve endoscopic assessment.👏 @ErasmusMC

Wishing you a joyful holiday season! 🎄 As we reflect with gratitude, we thank everyone who has been part of the AIDA journey, our team, collaborators, and supporters. Your contributions have pushed the boundaries of AI in advancing early detection of gastric cancer.

✨Dr. Tania Fleitas, AIDA’s Principal Investigator, hosted the autumn EORTC GI Group meeting in Valencia, bringing together leading experts for key discussions in gastrointestinal oncology. We’re proud to see AIDA represented in such an impactful collaboration. @incliva_iis

🎥 The final AIDA webinar is live! Miriam Cuatrecasas, Glória Fernández-Esparrach & Leticia Moreira explore precursor lesions of gastric cancer. 👉 Watch the full session with English subtitles: youtube.com/watch?v=OYjdYX…

In Memoriam: Dr Pelayo Correa (1927-2025) We mourn the loss of Dr Correa, a pioneering cancer researcher whose "Correa Cascade" revolutionised our understanding of gastric cancer. He established the definitive link between H. pylori infection and gastric cancer. Rest in peace.

Cancers diagnosed within 1 year after a negative endoscopy are considered missed gastric cancers. Even with skilled endoscopists, subtle lesions can be overlooked. AIDA combines expert gastroenterological knowledge with AI technology to ensure fewer cancers slip through.